Almirall to focus on respiratory and skin diseases
Catalan Economy
01 Jan 2010
Pharmaceutical group almirall is to focus its r+d investments on new treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (copd) and skin problems, particularly psoriasis and skin cancer.
according to almirall's development director pere berga, the company invested nearly eur 100 million in r&d in 2009. the lab also expects to finalize this year clinical trials for eklira, its new drug for copd. in 2009, almirall posted eur 701 million in revenue, with net profit reaching eur 141 million. the group has a team of 550 researchers at its three centers in sant feliu de llobregat, sant just desvern and sant andreu de la barca (barcelona).
source: expansión 25/01/2010
Related News and Success stories.
-
29 Oct 2025
See more Catalonia sets new strategy to attract €6 billion in foreign investment by 2030Catalonia sets new strategy to attract €6 billion in foreign investment by 2030
-
27 Oct 2025
See more Catalonia strengthens business ties with China in Industry 4.0 technologiesCatalonia strengthens business ties with China in Industry 4.0 technologies
-
26 Oct 2025
See more Chinese investment in Catalonia triples compared to the previous five-year periodChinese investment in Catalonia triples compared to the previous five-year period
-
23 Oct 2025
See more US company Elian to invest over €200 million to expand its plant-based protein facility in BarcelonaUS company Elian to invest over €200 million to expand its plant-based protein facility in Barcelona